219 related articles for article (PubMed ID: 15655555)
21. Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity.
van Meerten T; van Rijn RS; Hol S; Hagenbeek A; Ebeling SB
Clin Cancer Res; 2006 Jul; 12(13):4027-35. PubMed ID: 16818702
[TBL] [Abstract][Full Text] [Related]
22. High-grade, chemotherapy-resistant primary ovarian carcinoma cell lines overexpress human trophoblast cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized monoclonal anti-Trop-2 antibody.
Varughese J; Cocco E; Bellone S; Bellone M; Todeschini P; Carrara L; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
Gynecol Oncol; 2011 Jul; 122(1):171-7. PubMed ID: 21453957
[TBL] [Abstract][Full Text] [Related]
23. In vitro and in vivo pharmacology and pharmacokinetics of a human engineered monoclonal antibody to epithelial cell adhesion molecule.
Ammons WS; Bauer RJ; Horwitz AH; Chen ZJ; Bautista E; Ruan HH; Abramova M; Scott KR; Dedrick RL
Neoplasia; 2003; 5(2):146-54. PubMed ID: 12659687
[TBL] [Abstract][Full Text] [Related]
24. V gamma 9 V delta 2 T cell cytotoxicity against tumor cells is enhanced by monoclonal antibody drugs--rituximab and trastuzumab.
Tokuyama H; Hagi T; Mattarollo SR; Morley J; Wang Q; So HF; Moriyasu F; Nieda M; Nicol AJ
Int J Cancer; 2008 Jun; 122(11):2526-34. PubMed ID: 18307255
[TBL] [Abstract][Full Text] [Related]
25. Overexpression of epithelial cell adhesion molecule in primary, metastatic, and recurrent/chemotherapy-resistant epithelial ovarian cancer: implications for epithelial cell adhesion molecule-specific immunotherapy.
Bellone S; Siegel ER; Cocco E; Cargnelutti M; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
Int J Gynecol Cancer; 2009 Jul; 19(5):860-6. PubMed ID: 19574774
[TBL] [Abstract][Full Text] [Related]
26. E-cadherin expression on human carcinoma cell affects trastuzumab-mediated antibody-dependent cellular cytotoxicity through killer cell lectin-like receptor G1 on natural killer cells.
Yamauchi C; Fujii S; Kimura T; Kuwata T; Wada N; Mukai H; Matsumoto N; Fukayama M; Ochiai A
Int J Cancer; 2011 May; 128(9):2125-37. PubMed ID: 21387286
[TBL] [Abstract][Full Text] [Related]
27. Maitake Beta-Glucan Enhances the Therapeutic Effect of Trastuzumab via Antibody-Dependent Cellular Cytotoxicity and Complement-Dependent Cytotoxicity.
Masuda Y; Yamashita S; Nakayama Y; Shimizu R; Konishi M
Biol Pharm Bull; 2024; 47(4):840-847. PubMed ID: 38616114
[TBL] [Abstract][Full Text] [Related]
28. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin).
Sliwkowski MX; Lofgren JA; Lewis GD; Hotaling TE; Fendly BM; Fox JA
Semin Oncol; 1999 Aug; 26(4 Suppl 12):60-70. PubMed ID: 10482195
[TBL] [Abstract][Full Text] [Related]
29. Ep-CAM overexpression in breast cancer as a predictor of survival.
Gastl G; Spizzo G; Obrist P; Dünser M; Mikuz G
Lancet; 2000 Dec; 356(9246):1981-2. PubMed ID: 11130529
[TBL] [Abstract][Full Text] [Related]
30. Trastuzumab activates allogeneic or autologous antibody-dependent cellular cytotoxicity against malignant rhabdoid tumor cells and interleukin-2 augments the cytotoxicity.
Katsumi Y; Kuwahara Y; Tamura S; Kikuchi K; Otabe O; Tsuchiya K; Iehara T; Kuroda H; Hosoi H; Sugimoto T
Clin Cancer Res; 2008 Feb; 14(4):1192-9. PubMed ID: 18281554
[TBL] [Abstract][Full Text] [Related]
31. Effect of alemtuzumab on neoplastic B cells.
Golay J; Manganini M; Rambaldi A; Introna M
Haematologica; 2004 Dec; 89(12):1476-83. PubMed ID: 15590398
[TBL] [Abstract][Full Text] [Related]
32. Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance.
Barok M; Isola J; Pályi-Krekk Z; Nagy P; Juhász I; Vereb G; Kauraniemi P; Kapanen A; Tanner M; Vereb G; Szöllösi J
Mol Cancer Ther; 2007 Jul; 6(7):2065-72. PubMed ID: 17620435
[TBL] [Abstract][Full Text] [Related]
33. Monoclonal antibody 9C4 recognizes epithelial cellular adhesion molecule, a cell surface antigen expressed in early steps of erythropoiesis.
Lammers R; Giesert C; Grünebach F; Marxer A; Vogel W; Bühring HJ
Exp Hematol; 2002 Jun; 30(6):537-45. PubMed ID: 12063020
[TBL] [Abstract][Full Text] [Related]
34. Acquired immunodeficiency syndrome-associated lymphomas are efficiently lysed through complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity by rituximab.
Golay J; Gramigna R; Facchinetti V; Capello D; Gaidano G; Introna M
Br J Haematol; 2002 Dec; 119(4):923-9. PubMed ID: 12472569
[TBL] [Abstract][Full Text] [Related]
35. Analysis of in vitro ADCC and clinical response to trastuzumab: possible relevance of FcγRIIIA/FcγRIIA gene polymorphisms and HER-2 expression levels on breast cancer cell lines.
Boero S; Morabito A; Banelli B; Cardinali B; Dozin B; Lunardi G; Piccioli P; Lastraioli S; Carosio R; Salvi S; Levaggi A; Poggio F; D'Alonzo A; Romani M; Del Mastro L; Poggi A; Pistillo MP
J Transl Med; 2015 Oct; 13():324. PubMed ID: 26450443
[TBL] [Abstract][Full Text] [Related]
36. Trastuzumab mediates antibody-dependent cell-mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic HER2/neu breast cancer patients.
Petricevic B; Laengle J; Singer J; Sachet M; Fazekas J; Steger G; Bartsch R; Jensen-Jarolim E; Bergmann M
J Transl Med; 2013 Dec; 11():307. PubMed ID: 24330813
[TBL] [Abstract][Full Text] [Related]
37. An open-label, randomized phase II study of adecatumumab, a fully human anti-EpCAM antibody, as monotherapy in patients with metastatic breast cancer.
Schmidt M; Scheulen ME; Dittrich C; Obrist P; Marschner N; Dirix L; Schmidt M; Rüttinger D; Schuler M; Reinhardt C; Awada A
Ann Oncol; 2010 Feb; 21(2):275-282. PubMed ID: 19633042
[TBL] [Abstract][Full Text] [Related]
38. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer.
Musolino A; Naldi N; Bortesi B; Pezzuolo D; Capelletti M; Missale G; Laccabue D; Zerbini A; Camisa R; Bisagni G; Neri TM; Ardizzoni A
J Clin Oncol; 2008 Apr; 26(11):1789-96. PubMed ID: 18347005
[TBL] [Abstract][Full Text] [Related]
39. A nonfucosylated anti-HER2 antibody augments antibody-dependent cellular cytotoxicity in breast cancer patients.
Suzuki E; Niwa R; Saji S; Muta M; Hirose M; Iida S; Shiotsu Y; Satoh M; Shitara K; Kondo M; Toi M
Clin Cancer Res; 2007 Mar; 13(6):1875-82. PubMed ID: 17363544
[TBL] [Abstract][Full Text] [Related]
40. The biology of the 17-1A antigen (Ep-CAM).
Balzar M; Winter MJ; de Boer CJ; Litvinov SV
J Mol Med (Berl); 1999 Oct; 77(10):699-712. PubMed ID: 10606205
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
